Gene Expression in Hepatocellular Carcinoma: Pilot Study of Potential Transarterial Chemoembolization Response Biomarkers

摘要: Abstract Purpose To perform a feasibility study to explore the relationship between hepatocellular carcinoma genetics and transarterial chemoembolization treatment response identify potential biomarkers associated with enhanced efficacy. Materials Methods In this single-institution study, pretreatment biopsy specimens for tumors in 19 patients (14 men, five women; mean age, 59 y) treated 2007 2013 were analyzed panel of 60 chemotherapy-sensitivity, hypoxia, mitosis, inflammatory genes QuantiGene Plex 2.0 mRNA detection assay. Demographic, disease, procedure data tumor outcomes collected. Quantitative levels compared based on radiologic exhibiting complete (CR) versus partial (PR). Results The sample included from (mean size, 3.0 cm; grade 1, n=6; 2, n=9; 3, n=4) two conventional sessions. Thirteen six exhibited CR PR, respectively, at 116 days after treatment. Tumors showed significant increase ( P ATF4 , BAX CCNE1 KIF11 NFX1 PPP3CA SNX1 TOP2A TOP2B ) gene expression addition lower CXCL10 (0.48-fold), had significantly VEGFA levels. Conclusions Genetic signatures may allow prechemoembolization stratification probability, analysis therefore offer an opportunity personalize locoregional therapy by enhancing modality allocation. Further corroboration identified markers exploration their respective predictive capacity thresholds is necessary.